Last reviewed · How we verify
Atacicept: with loading dose
CD28/B7 costimulation blockade
CD28/B7 costimulation blockade Used for Rheumatoid arthritis.
At a glance
| Generic name | Atacicept: with loading dose |
|---|---|
| Sponsor | EMD Serono |
| Drug class | B cell depleting agent |
| Target | CD28/B7 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Atacicept is a recombinant protein that blocks the interaction between CD28 and B7 molecules, thereby inhibiting T-cell activation and proliferation.
Approved indications
- Rheumatoid arthritis
Common side effects
- Injection site reaction
- Headache
- Fatigue
Key clinical trials
- Atacicept in Multiple Sclerosis Extension Study, Phase II (PHASE2)
- A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) (PHASE2)
- Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) (PHASE2, PHASE3)
- Atacicept in Subjects With Optic Neuritis (PHASE2)
- Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II) (PHASE2)
- A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |